Trump posts video endorsing CBD for seniors. Researchers urge caution.
The video jolted the cannabis industry, sending stocks soaring and raising hopes that the president will take a permissive approach to marijuana.
Pharmaceutical
Articles
Drug made from marijuana reduced back pain in large study
The 800-patient study by a German drugmaker is the latest evidence of the therapeutic properties of cannabis, which remains illegal under U.S. federal law even as most states have made it available for medical or recreational use.
What new tariffs mean for pharmaceuticals, patented drugs
President Donald Trump’s announcement that his administration will impose a 100 percent tariff on patented pharmaceutical products sparked confusion Friday, as government officials, drug companies and trade groups sought clarity on how the levy would be applied.
Eli Lilly plans to make highly anticipated weight-loss pill at new $6.5B Texas plant
The $6.5 billion Houston-area plant is part of the drugmaker’s commitment to add four U.S. manufacturing sites through a $27 billion reshoring investment unveiled early this year.
Pfizer amps up push into obesity treatments with $4.9B deal for Metsera
Demand for obesity treatments has soared recently, due to unprecedented weight loss provided by regular injections of market leaders Wegovy from Novo Nordisk and Zepbound from Indianapolis-based Eli Lilly and Co.
Weight-loss drugs can cut future health costs. The fight is over who pays now.
Evidence from clinical trials shows that GLP-1s have benefits beyond weight loss, preventing related chronic conditions and ultimately blunting health-plan costs. But the savings might take decades, experts say.
Trial shows Lilly rival’s weight-loss pill could deliver same results as shots as companies race to market
Ahead of decisions by the FDA, both Novo Nordisk and Eli Lilly are readying production for their weight-loss pills, having been unable to keep up with demand for their shots that exploded in popularity.
Lilly’s GLP-1 pill beats older Novo diabetes drug in head-to-head trial
Eli Lilly and Co. and Novo Nordisk have been locked in a fierce battle to control the obesity market, which is projected to reach $100 billion by the end of the decade.
Eli Lilly to build $5B plant in Virginia—first of 4 U.S. sites to be named this year
Indianapolis-based Lilly said the new plant would create more than 650 jobs in Virginia for engineers, scientists, operations personnel and lab technicians, as well as 1,800 construction jobs.
Health insurance premiums poised to spike over drug costs, tariff threats
In explaining the rising prices, insurers and employers point to two recent factors: the tariffs on pharmaceutical imports and the high cost of new obesity treatments.
Trump’s plan for drug advertising crackdown faces many hurdles
President Donald Trump signed a memo Tuesday that directs the FDA and other agencies to step up enforcement against ubiquitous prescription drug ads on TV, websites and social media.
Lilly rival Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs
The restructuring, which would eliminate 11% of the company’s workforce, aimed to reduce organizational complexity and speed up decision-making as the company faces a more competitive market for obesity drugs.
Elanco reports pet parasite treatment quickly hit $100M blockbuster status
The sales momentum comes as Elanco prepares to open its $200 million-plus corporate campus next month on the west side of downtown Indianapolis.
World Health Organization adds Mounjaro to its list of essential medicines
The recommendation applies to a range of GLP-1 drugs that also includes Novo Nordisk’s Ozempic and Lilly’s older diabetes treatment, Trulicity.
Trump plans hefty tax on imported drugs, risking higher prices, shortages
The threat comes as Trump also pressures drugmakers to lower prices of pharmaceuticals in the United States.
Mounjaro price hike fuels UK pharmacy battle to retain customers
Eli Lilly and Co. announced this month it would raise the weight-loss treatment’s price by as much as 170%, presenting pharmacies with a dilemma about how much they would pass on to patients.
Lilly’s weight-loss pill moves ahead after pivotal trial
The company’s shares rose as much as 4.3% Tuesday after Eli Lilly announced the trial results for orforglipron.
Lilly signs $1.3B deal with Boston startup for AI-assisted drug development
Superluminal will use its AI-driven platform to discover and optimize small-molecule treatments for G protein-coupled receptors, or GPCRs, which have emerged as a key to conditions such as diabetes and obesity.
Firm tied to Trump Jr. debuts direct sales product for pharma companies
Eli Lilly and Co. has already launched LillyDirect service, which CEO David Ricks says jibes with the administration’s demand for direct sales. Lilly is working with Truepill and Amazon.com Inc.’s pharmacy unit on its platform.
Research on reversing Alzheimer’s reveals lithium as potential key
Seven years of investigation by scientists at Harvard Medical School has revealed that the loss of the metal lithium plays a powerful role in Alzheimer’s disease, a finding that could lead to earlier detection, new treatments and a broader understanding of how the brain ages.